help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 4, 336-341, April 2006; doi:10.1634/theoncologist.11-4-336
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rocconi, R. P.
Right arrow Articles by Alvarez, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rocconi, R. P.
Right arrow Articles by Alvarez, R. D.

Gynecologic Oncology

Pegylated Liposomal Doxorubicin Consolidation Therapy after Platinum/Paclitaxel-Based Chemotherapy for Suboptimally Debulked, Advanced-Stage Epithelial Ovarian Cancer Patients

Rodney P. Rocconi, J. Michael Straughn, Jr., Charles A. Leath, III, Larry C. Kilgore, Warner K. Huh, Mack N. Barnes, III, Edward E. Partridge, Ronald D. Alvarez

University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Birmingham, Alabama, USA

Key Words. Ovarian cancer • Chemotherapy • Consolidation therapy • Doxorubicin

Correspondence: Rodney P. Rocconi, M.D., University of Alabama at Birmingham, 618 19th Street South, Old Hillman Building, Room 538, Birmingham, Alabama 35233, USA. Telephone: 205-934-4986; Fax: 205- 975-6174; e-mail: rocconi{at}uab.edu

Objective. To assess the feasibility of using pegylated liposomal doxorubicin (PLD) as a consolidation therapy in patients with advanced ovarian cancer who have attained a clinically defined complete response to initial platinum/paclitaxel-based chemotherapy.

Methods. Patients diagnosed with suboptimally debulked stage IIIC/IV epithelial ovarian cancer who attained a clinically defined complete response at the completion of platinum/paclitaxel-based chemotherapy were eligible for this protocol. Patients were treated with PLD at a dose of 40 mg/m2 every 28 days for four cycles. A survival analysis was calculated using the Kaplan-Meier method.

Results. Of the 30 patients enrolled, 29 were evaluable. Twenty-three patients (79%) completed all four cycles of consolidation therapy. Palmar-plantar erythrodysesthesia was the most common toxicity. Six patients remained clinically without evidence of disease with a median follow-up of 35 months from the completion of primary chemotherapy. The median progression-free interval was 15 months, and median overall survival time was 31 months, with 47% of patients achieving a 4-year survival.

Conclusions. Consolidation therapy with PLD chemotherapy administered to women with advanced epithelial ovarian cancer after initial chemotherapy appears feasible based on its toxicity profile. Considering the tolerability of this agent, further investigation is needed to depict the optimal dose and schedule needed for consolidation therapy.




This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
H. S. Kim, N.-H. Park, H. H. Chung, J. W. Kim, Y.-S. Song, and S.-B. Kang
Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin?
Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 445 - 450.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. Hamm
Pegylated Liposomal Doxorubicin Consolidation Therapy
Oncologist, July 1, 2006; 11(7): 855 - 855.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.